Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 26, Issue 8, Pages 1128-1135Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881111435251
Keywords
Dopamine D2 receptor; occupancy; antipsychotic drug; JNJ-37822681; [C-11]raclopride; PET
Funding
- Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
Ask authors/readers for more resources
JNJ-37822681 is a novel, fast-dissociating dopamine D-2 receptor antagonist, currently in development as an antipsychotic drug candidate. A previous first-in-human study demonstrated mild central nervous system effects of JNJ-37822681 in healthy male volunteers. Significant but transient serum prolactin elevations were demonstrated, whereas other neurophysiological effects were relatively small. To investigate striatal dopamine D-2 receptor occupancy by variable single doses of JNJ-37822681, an open-label [C-11]raclopride positron emission tomography study was performed in 12 healthy male volunteers, using the simplified reference tissue model with cerebellum as reference tissue. Oral administration of JNJ-37822681 resulted in dose-dependent dopamine D-2 receptor occupancy. Receptor occupancy increased from 9-19% at 2 mg doses to 60-74% at 20 mg doses of JNJ-37822681. Therefore, single oral doses of JNJ-37822681 can produce occupancy levels that are generally associated with clinical efficacy for registered antipsychotic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available